Late Discovery & Investigative Research
NGT BioPharma Consultants understand the challenges companies face when selecting a candidate molecule(s) to advance into preclinical development. To increase the efficiency and effectiveness of this process, we work collaboratively with our clients to provide a clear assessment of a potential asset’s attributes, including risks, to ensure critical experiments are prioritized.
We generate fit-for-purpose late discovery and investigative research plans for our clients by leveraging our team’s collective knowledge and experience in small and large molecules (Mabs, duobodies, proteins, cell therapy, gene therapy, and other new modalities). Our advice, and recommendations, also leverages our broader team’s drug development expertise in the Nonclinical Sciences, CMC, Regulatory and Quality/Compliance disciplines.
- Assess data packages for risks and gaps, and develop mitigation strategies
- Coordinate and oversee outsourcing of studies necessary to commit resources for preclinical development
- Develop strategies to identify back-up potential candidates
- Review and evaluate Intellectual Property
- Assess pharmacology data and its ability to translate to human disease
- Provide target, disease, and/or competitor landscape analyses to inform strategic decision making
- Analyze potential financing strategies; develop investment solicitation materials
Although NGT is neither a laboratory or manufacturing services provider, we can serve as your single point of contact to our network of reputable CROs and CDMOs.
